InvestorsHub on MSN

Johnson & Johnson’s IMAAVY demonstrates durable disease control in myasthenia gravis

Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension (OLE) in a broad population of antibody-positive (including anti-AChR+a and ...

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

The generalized myasthenia gravis treatment pipeline features several promising late-stage candidates, including IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), ...

Johnson & Johnson: IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ ...